Amphista Therapeutics Ltd has expanded its research team with the appointment of Martin O’Rourke as head of drug discovery and James Osborne as director of chemistry. Located in Glasgow, UK, Amphista is developing small molecule drugs for cancer. Dr O’Rourke was most recently a director in the oncology bioscience group at AstraZeneca Plc. Prior to this, he was senior director of in vitro oncology at Charles River in the UK. Dr Osborne led discovery at GW Pharmaceuticals, recently acquired by Jazz Pharmaceuticals Plc.
Amphista announced the appointments on 28 June 2021.
Copyright 2021 Evernow Publishing Ltd